FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* TURKEL CATHERINE C.						2. Issuer Name and Ticker or Trading Symbol Novus Therapeutics, Inc. [NVUS]							of Reporting cable) or (give title	g Pers	on(s) to Issu 10% Ow Other (s	ner
(Last) (First) (Middle) C/O NOVUS THERAPEUTICS, INC. 19900 MACARTHUR BLVD., SUITE 550					3. Date of Earliest Transaction (Month/Day/Year) 09/26/2019							X Office (give title Office (specify below) President				
(Street) IRVINE CA 92612 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date)				. Transacti Date Month/Day	ction 2A. Deemed Execution Date,			3. Transactic Code (Ins 8)	4. Securi Disposed 5)	curities Acquired (A) o ssed Of (D) (Instr. 3, 4 and the state of the		5. Amou Securitie Beneficie Owned F Reported Transact (Instr. 3 a	5. Amount of Securities For (D). (O). (O). (O). (D). (D). (D). (D). (D). (D). (D). (D		: Direct Control of the control of t	'. Nature of Indirect Seneficial Dwnership Instr. 4)
								uirea, Dis s, options,				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo	Cod	saction e (Instr.			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Cod	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$0.67	09/26/2019		A		75,000		(1)	09/26/2029	Common Stock	75,000	\$0.00	75,000	0	D	

Explanation of Responses:

1. This option represents a right to purchase a total of 75,000 shares of the Issuer's Common Stock, which will vest in equal installments on the first and second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Remarks:

/s/ Ryan A. Murr, as attorneyin-fact for Catherine C. Turkel

09/30/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.